Use of patient-reported outcome measures in cost-effectiveness models informing health technology assessments of non-oncology treatments: a review Including patient-reported outcome measures (PROMs) in cost-effectiveness models (CEMs) represents an important opportunity to reflect patients’ perspectives in health technology assessments (HTAs)...

🚨 Available now🚨

Our latest review provides an essential insight into how #patientreportedoutcomemeasures can be included in #costeffectiveness models that inform #healthtechnologyassessments of non-oncology treatments.

Read it here 👉 www.tandfonline.com/doi/full/10....

5 ways to address pricing and access challenges across the European landscape EVERSANA discuss 5 effective strategies for overcoming pricing and access challenges in the European healthcare landscape. Learn about HTA, risk-sharing, data utilisation, orphan drugs, and more.

From prolonged timelines for #HealthTechnologyAssessments to disparities in #access between wealthier and less affluent nations in #Europe - Paolo Correale provides an overview of the current landscape and impact on #patientaccess.
#pricing #reimbursement #EVERSANA

pharmaphorum.com/market-acces...

Wieso wir immer noch ineffiziente medizinische Behandlungen finanzieren Der Bund prüft zweifelhafte medizinische Leistungen. Sogenannte Health Technology Assessments werden gerne zum Heilsbringer für effiziente Medizin erklärt und als bestes Mittel zur Kostenreduktion. Le...

Wieso wir immer noch ineffiziente medizinische Behandlungen finanzieren

Sogenannte #HealthTechnologyAssessments werden gerne zum Heilsbringer für effiziente #Medizin erklärt und als bestes Mittel zur #Kostenreduktion

www.watson.ch/schweiz/anal...